Silvercrest Asset Management Group LLC Has $2.71 Million Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Silvercrest Asset Management Group LLC lessened its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 4.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,905 shares of the company’s stock after selling 1,800 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Henry Schein were worth $2,712,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HSIC. Mather Group LLC. acquired a new stake in Henry Schein in the first quarter worth about $97,000. Palisade Asset Management LLC bought a new stake in shares of Henry Schein during the first quarter worth approximately $113,000. Benjamin F. Edwards & Company Inc. lifted its holdings in Henry Schein by 37.8% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,516 shares of the company’s stock valued at $114,000 after buying an additional 416 shares during the period. Covestor Ltd boosted its stake in Henry Schein by 12.8% in the first quarter. Covestor Ltd now owns 1,511 shares of the company’s stock valued at $114,000 after acquiring an additional 171 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Henry Schein during the 4th quarter worth $115,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Up 1.4 %

Shares of HSIC stock opened at $72.44 on Wednesday. Henry Schein, Inc. has a 12-month low of $60.01 and a 12-month high of $82.63. The company has a quick ratio of 1.02, a current ratio of 1.75 and a debt-to-equity ratio of 0.47. The firm has a fifty day moving average of $68.03 and a 200-day moving average of $71.81. The company has a market capitalization of $9.28 billion, a price-to-earnings ratio of 24.47, a P/E/G ratio of 1.76 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.21 EPS. As a group, equities research analysts predict that Henry Schein, Inc. will post 5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. UBS Group cut their price target on Henry Schein from $82.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. Piper Sandler restated an “overweight” rating and set a $86.00 target price on shares of Henry Schein in a report on Friday, June 21st. Barrington Research reaffirmed an “outperform” rating and issued a $92.00 price target on shares of Henry Schein in a research note on Friday, July 5th. Baird R W upgraded shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Evercore ISI decreased their price objective on shares of Henry Schein from $75.00 to $72.00 and set an “in-line” rating for the company in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $81.67.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.